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Introduction: This study evaluated the efficacy, safety, and pharma-
cokinetics of conatumumab combined with paclitaxel-carboplatin 
(PC) as first-line treatment for advanced non–small-cell lung cancer 
(NSCLC).
Methods: Patients (aged >18 years) with previously untreated 
advanced or recurrent NSCLC were randomized 1:1:1 (stratified by 
Eastern Cooperative Oncology Group performance status and disease 
stage) to receive up to six 3-week cycles of PC combined with cona-
tumumab (arm 1, 3 mg/kg; arm 2, 15 mg/kg) or placebo (arm 3) every 
3 weeks. The primary endpoint was progression-free survival (PFS). 
This study is registered with ClinicalTrials.gov (NCT00534027).
Results: Between August 8, 2007 and April 9, 2009, 172 patients were 
randomized (arm 1, n = 57; arm 2, n = 56; arm 3, n = 59). Median PFS 
was 5.4 months (95% confidence interval [CI] 4.1–6.3) in arm 1 (haz-
ard ratio [HR] 0.84 [95% CI 0.57–1.24]; p = 0.41), 4.8 months (95% 
CI 3.2–6.5) in arm 2 (HR 0.93 [0.64–1.35]; p = 0.57), and 5.5 months 
(95% CI 4.3–5.7) in arm 3. There was an interaction between tumor 
histology and the effect of conatumumab on PFS (squamous HR 
0.47 [0.23–0.94]; nonsquamous HR 1.08 [0.74–1.57]; interaction p = 
0.039).The most common grade of three or more adverse events were 
neutropenia, anemia, and thrombocytopenia. There was no evidence 
of pharmacokinetic interactions between conatumumab and PC. Of 
158 patients assessable for FCGR3A polymorphisms, conatumumab 
treatment was associated with a trend toward longer overall survival 
(HR 0.72 [0.43–1.23]) among V-allele carriers (V/V or F/V; n = 54) 
but not among F-allele homozygotes (n = 34; HR 1.37 [0.66–2.86]).
Conclusion: Although well tolerated, the addition of conatumumab 
to PC did not improve outcomes in unselected patients with previ-
ously untreated advanced NSCLC.
Key Words: conatumumab, paclitaxel, carboplatin, non–small-cell 
lung cancer, death receptor 5.
(J Thorac Oncol. 2013;8: 329-337)
First-line treatments for non–small-cell lung cancer (NSCLC) include platinum-based chemotherapy alone or 
combined with targeted agents (e.g., bevacizumab).1 However, 
median overall survival (OS) with current therapies is poor,2 
and investigation of novel treatments is warranted.
Apoptosis is regulated through the intrinsic pathway by 
mitochondrial signals after cell stress and through the extrin-
sic pathway by ligand-mediated activation of proapoptotic 
death receptors (DRs).3 The efficacy of cytotoxic therapies, 
which inhibit cell proliferation and induce apoptosis through 
the intrinsic pathway, is limited by the development of resis-
tance by NSCLC cells.3,4 A number of agonists of DR4 and 
DR5, which target the extrinsic pathway, are in develop-
ment for the treatment of solid tumors, including lung can-
cer (Supplemental Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A370).5,6
Conatumumab, an investigational, fully human, 
monoclonal agonistic antibody of human DR5, has shown 
activity against NSCLC xenografts.7 In the first-in-human 
study, conatumumab monotherapy had acceptable toxicity 
up to a target dose of 20 mg/kg every 2 weeks and exhibited 
evidence of antitumor activity in patients with advanced 
solid tumors, including a confirmed partial response in a 
patient with NSCLC.8 In a phase 1b study, conatumumab 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0803-0329
A Randomized Phase 2 Study of Paclitaxel and Carboplatin 
with or without Conatumumab for First-Line Treatment of 
Advanced Non–Small-Cell Lung Cancer
Luis Paz-Ares, MD,* Beatrix Bálint, MD,† Richard H. de Boer, MBBS,‡ Jan P. van Meerbeeck, MD, PhD,§ 
Rafal Wierzbicki, MD,ǁ Paul De Souza, MBBS,¶ Francesco Galimi, MD, PhD,# Vincent Haddad, MS,** 
Tony Sabin, MS,** Yong-jiang Hei, MD, PhD,# Yang Pan, PhD,†† Susan Cottrell, PhD,††  
Cheng-Pang Hsu, PhD,# and Rodryg RamLau, MD, PhD‡‡
Accepted for publication November 06, 2012
*Department of Medical Oncology, IBIS & Hospital Universitario Virgen 
del Rocio/CSIC/Universidad de Sevilla, Servicio de Oncología, Sevilla, 
Spain; †Csongrád County Hospital of Chest Diseases, Deszk, Hungary; 
‡Department of Medical Oncology, Royal Melbourne and Western 
Hospitals, Melbourne, Australia; §Department of Respiratory Medicine, 
Universitair Ziekenhuis Gent, Gent, Belgium; ǁR.S. McLaughlin 
Durham Regional Cancer Centre Oshawa, Ontario, Canada; ¶University 
of Western Sydney, School of Medicine, Penrith, New South Wales, 
Australia; #Amgen Inc., Thousand Oaks, California; **Amgen Ltd., 
Cambridge, United Kingdom; ††Amgen Inc., Seattle, Washington; and 
‡‡Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan 
University of Medical Sciences, Poland.
Disclosure: Dr. Paz-Ares received compensation from Amgen Inc for his 
role as a consultant and advisor, and his work was partially financed by 
the Spanish Ministry of Health (ISCiii PI 081156, PI 1102688). Dr. de 
Boer has received research funding from Amgen Inc. Dr. De Souza has 
received honoraria from Amgen Inc. Drs. Galimi, Haddad, Sabin, Hei, 
Pan, Cottrell, and Hsu are employees of and shareholders in Amgen Inc. 
All other authors declare no conflict of interest.
Address for correspondence: Luis Paz-Ares, MD, Servicio de Oncologia 
Médica Hospital Universitario Virgen del Rocio, Av. Manuel Siurot SN, 
41013 Sevilla, Spain. E-mail: lpazares@hotmail.com
ORIGINAL ARTICLE
330 Copyright © 2013 by the International Association for the Study of Lung Cancer
Paz-Ares et al. Journal of Thoracic Oncology  •  Volume 8, Number 3, March 2013
combined with paclitaxel and carboplatin (PC) as a first-
line therapy was well tolerated and had antitumor activity in 
patients with advanced NSCLC.9,10 This phase 2 portion of the 
study evaluated the efficacy, safety, and pharmacokinetics of 
conatumumab combined with PC in this setting. Exploratory 
biomarkers were assessed.
PATIENTS AND METHODS
Study Design and Patients
Eligible patients (aged ≥18 years) had previously 
untreated (except adjuvant chemotherapy completed ≥1 year 
before enrollment) histologically or cytologically confirmed 
advanced (stage IIIB with malignant pleural effusion or stage 
IV) or recurrent (disease progression after complete surgical 
resection for stage I/II disease) NSCLC; Eastern Cooperative 
Oncology Group performance status (ECOG PS) of 0 or 1; 
adequate hematologic, hepatic, cardiac, and renal function. 
Key exclusion criteria included untreated or unstable central 
nervous system metastases; history of other cancers (except 
curatively treated nonmelanoma skin cancer or in situ cervical 
cancer) unless curatively treated with no therapy or evidence 
of disease for 3 or more years; arterial thrombosis, pulmonary 
embolism, deep vein thrombosis, or hemorrhagic disorders 
within 28 days of enrollment; and prior immunotherapy or 
investigational therapy for advanced NSCLC. Patients pro-
vided written informed consent. Institutional review board 
approval was obtained for all procedures.
Randomization and Masking
This randomized, placebo-controlled, phase 2 study 
was conducted at 41 centers in North America, Europe, and 
Australia and was the second part of a phase 1b/2 study. 
The results of the phase 1b study have been reported.10,11 
Patients were randomLy assigned 1:1:1 to three treatment 
arms. Randomization was stratified by ECOG PS (0 or 1) and 
 disease stage (IIIB or IV/recurrent). Centralized randomiza-
tion with a permuted block design was used. Patients, inves-
tigators, study monitors, and the study team were blinded to 
treatment assignment.
Procedures
Two doses of conatumumab were assessed. Patients 
received up to six cycles of paclitaxel (200 mg/m2) and car-
boplatin (area under the curve, 6 mg/mL·min) intravenously 
every 3 weeks combined with intravenously administered 
conatumumab 3 mg/kg (arm 1), conatumumab 15 mg/kg 
(arm 2), or placebo (arm 3) on day 1 of each cycle. Patients 
who completed up to six cycles of PC or discontinued 
PC owing to chemotherapy-related toxicity continued to 
receive conatumumab or placebo monotherapy until disease 
 progression, intolerable toxicity, withdrawal of consent, or 
30 months from the first treatment date. The planned cona-
tumumab doses were the maximum tested dose (15 mg/kg; 
arm 2) in the phase 1b study9,10 and a lower dose (3 mg/kg; 
arm 1) based on safety and pharmacokinetic data in the first-
in-human study.8
No dose reductions for conatumumab were planned. 
Conatumumab and placebo were withheld until grade 3 or 
higher alanine aminotransferase or aspartate aminotransfer-
ase increases, or grade 4 amylase/lipase increases improved to 
grade 1 or lesser; they were discontinued if withheld for more 
than 42 days. Conatumumab and placebo were discontinued 
for grade 3 or higher alanine aminotransferase or aspartate 
aminotransferase greater than 10 times the upper limit of nor-
mal or grade 4 amylase or lipase increases persisting for more 
than 7 days. Chemotherapy doses were reduced or withheld 
(≤21 days) for hematologic or nonhematologic toxicities. If 
chemotherapy was withheld, conatumumab and placebo were 
withheld, until chemotherapy was resumed.
Tumor response was assessed by investigators per mod-
ified Response Evaluation Criteria in Solid Tumors, version 
1.0.12 Computed tomography or magnetic resonance imaging 
was performed at screening and every 6 ± 1 weeks through 
long-term follow-up (36 months from randomization of the 
last patient). Reponses were confirmed in more than 4 weeks 
after criteria were met. Stable disease was confirmed not ear-
lier than 35 days after enrollment.
All adverse events (AEs) from enrollment until the 
safety follow-up visit (30 days after the last dose of study treat-
ment) were recorded and graded according to National Cancer 
Institute Common Terminology Criteria for Adverse Events, 
version 3.0. Serum was collected predose on day 1 of cycles 1 
and 3, every two cycles thereafter, and at follow-up visits (30, 
60, and 90 days after the last dose), and anti-conatumumab 
antibodies were assessed using an electrochemiluminescence 
bridging immunoassay8
Serum for conatumumab pharmacokinetics (from 
patients in the phase 1b and phase 2 studies) were collected 
predose and immediately before the end of infusion on day 1 
of cycles 1 and 2; at 3, 24, and 168 hours postdose on day 1 of 
cycle 1; predose on day 1 of cycles 3 and 5; and at follow-up 
visits (30 and 60 days after the last dose). Plasma for paclitaxel 
and carboplatin pharmacokinetics (phases 1b and 2) was col-
lected predose and immediately before the end of infusion on 
day 1 of cycles 1 and 2, and at 3 hours and 24 hours postdose on 
day 1 of cycle 1. Pharmacokinetic parameters were estimated 
using noncompartmental methods and WinNonlin Enterprise 
software, version 5.1.1 (Pharsight Corp., Mountain View, CA).8
DNA from blood samples was used for FCGR3A 
V158F single-nucleotide polymorphism genotyping by allelic 
discrimination assay (see Appendix, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A376).
Statistical Analysis
The primary endpoint was progression-free survival 
(PFS; time from randomization to disease progression per 
modified Response Evaluation Criteria in Solid Tumors 
version 1.012 or death). Secondary endpoints included OS (time 
from randomization to death), objective response rate (ORR; 
complete plus partial response for patients with measurable 
disease at baseline), duration of response, time to response, 
incidence of AEs and laboratory abnormalities, conatumumab 
pharmacokinetics, and anti-conatumumab antibody formation. 
Exploratory endpoints included an analysis of genetic variations 
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in FCGR3A. Additional prespecified analyses (interaction 
between squamous and nonsquamous tumor histology and 
outcome; 4.5- and 6.0-month survival rates) and ad hoc 
analyses (interaction between conatumumab monotherapy and 
outcome) are reported.
Randomization of 150 patients was planned. The pri-
mary analysis was conducted after 120 PFS events. Assuming 
a 12-month uniform accrual period, a common exponential 
dropout rate parameter of 0.003 (accounting for a predicted 
10% of patients lost to follow-up over 3 years), and expo-
nential PFS curves, the approximate precision for primary 
analysis estimates of the hazard ratio (HR) for each treatment 
comparison was determined by trial simulation. Assuming 
median PFS of 6.5 months for arms 1 and 2, 4.5 months for 
arm 3 (HR 0.692), and no difference between treatment arms 
(HR 1.0), 95% CIs for the comparison of arms 1 and 2 indi-
vidually with arm 3 were expected to be 0.45 to 1.08 and 0.65 
to 1.55, respectively. This study was designed to estimate the 
treatment effect (assessed by PFS) of adding conatumumab 
to PC, rather than to test formal inferences. Survival data are 
from the updated analysis (March 15, 2010); other data are 
from the primary analysis (July 28, 2009).
Efficacy endpoints were assessed for the intent-to-treat 
population. Safety analyses included all patients who received 
at least one dose of investigational product. Time-to-event 
endpoints were summarized using Kaplan-Meier methods. 
Primary analyses of PFS and OS were conducted using Cox 
proportional hazards models stratified by ECOG PS (0 or 1) 
or disease stage (IIIB or recurrent). Differences between arms 
1 and 2 (individually or combined) and arm 3 were estimated 
with HRs and 95% CIs. Patients without a PFS event were 
censored at the date of last tumor evaluation. For OS analyses, 
patients who had not died or were lost to follow-up were cen-
sored at their last contact day. The Tarone trend test was used 
to assess the conatumumab dose response for time-to-event 
endpoints. CIs for ORR were calculated using the Clopper 
Pearson method. Differences in ORRs and corresponding 
95% CIs estimated with the Newcombe Wilson method were 
generated for each treatment comparison. The strength of the 
ORR dose response was assessed using the Cochran Armitage 
trend test. This study is registered with ClinicalTrials.gov 
(NCT00534027).
RESULTS
Between January 28, 2008 and April 9, 2009, 172 
patients were randomized (arm 1, n = 57; arm 2, n = 56; arm 3, 
n = 59) (Fig. 1). Patient demographics and baseline character-
istics were generally similar among treatment arms. However, 
there were fewer current smokers in arm 2 (Table 1). A total of 
167 of 172 patients (97%) received conatumumab or placebo. 
Eighty-eight patients received maintenance monotherapy (arm 
1, n = 29; arm 2, n = 29; arm 3, n = 30). As of June 7, 2011, all 
patients had discontinued treatment. The median (range) rela-
tive dose intensity (actual versus planned) of conatumumab in 
arms 1 and 2 was 0.95 (0.7–1.1) and 0.94 (0.7–1.0), respec-
tively, for patients who received maintenance monotherapy, 
210 patients screened
38 excluded
172 randomized
57 conatumumab 3 mg/kg + PC
56 received conatumumab
1
56 conatumumab 15 mg/kg + PC 59 placebo + PC
58 received placebo
1 did not receive placebo
53 discontinued
41 disease progression
6 adverse event
2 death
56 discontinued
41 disease progression
5 adverse event
2 death
 did not receive conatumumab
53 received conatumumab
3 did not receive conatumumab
58 discontinued
44 disease progression
4 consent withdrawn
4 adverse event
2 consent withdrawn
2 other
1 consent withdrawn
1 ineligibility determined
1 protocol deviation
1 lost to follow-up
1 administrative decision
3 other
2 death
1 ineligibility determined
1 administrative decision
1 alternative therapy
1 other
0 still receiving treatment0 still receiving treatment 0 still receiving treatment
FIGURE 1.  Consolidated Standards of Reporting Trials (CONSORT) diagram. PC, paclitaxel and carboplatin.
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and 1.0 (0.6–1.1) and 1.01 (0.8–1.1) mg/kg for those who did 
not. Second-line chemotherapy was  subsequently reported for 
25 of 57 patients (44%) in arm 1, 26 of 56 patients (46%) in 
arm 2, and 20 of 59 patients (34%) in arm 3.
At the time of the primary analysis, the HR (95% CI) 
for PFS versus arm 3 was 1.06 (0.68–1.66; p = 0.84) for arm 
1, and 1.00 (0.64–1.55; p = 1.00) for arm 2. All other data 
presented are from the updated analysis. At the time of the 
updated analysis, 163 of 172 (95%) patients had disease pro-
gression or had died. The HR (95% CI) for PFS versus arm 3 
was 0.84 (0.57–1.24; p = 0.41) for arm 1 and 0.93 (0.64–1.35; 
p = 0.57) for arm 2 (Table 2, Fig. 2A). The HR (95% CI) for 
OS versus arm 3 was 0.80 (0.52–1.24; p = 0.28) for arm 1, and 
0.84 (0.54–1.30; p = 0.51) for arm 2 (Table 2, Fig. 2B). There 
were no apparent dose-related trends in PFS and OS among 
treatment arms.
In a prespecified analysis of the intent-to-treat popula-
tion, there was an interaction between squamous/nonsqua-
mous cell histology and treatment arm, indicating improved 
PFS with the addition of conatumumab to PC (HR [95% CI] 
for squamous histology, 0.47 [0.23–0.94], and nonsquamous 
histology, 1.08 [0.74–1.57]; interaction p = 0.039; Fig. 3A). 
A similar trend was observed for OS (HR [95% CI] for squa-
mous histology, 0.51 [0.24–1.08], and nonsquamous histol-
ogy, 0.92 [0.59–1.44]; interaction p = 0.284; Fig. 3B).
In planned piecewise analyses with cut points at 
4.5 months for PFS and 6 months for OS, a treatment effect 
was observed during the latter period (Supplemental Table 
2, Supplemental Digital Content 3, http://links.lww.com/
JTO/A371). An ad hoc analysis also suggested a treatment 
effect on PFS and OS for conatumumab among patients who 
received maintenance monotherapy (Supplemental Table 3, 
TABLE 1.  Patient Demographic and Baseline Characteristics
Arm 1
PC + 3 mg/kg 
Conatumumab (n = 57)
Arm 2
PC + 15 mg/kg 
Conatumumab (n = 56)
Arm 3
PC + Placebo 
(n = 59)
Sex, n (%)
 Male 40 (70) 35 (63) 41 (69)
 Female 17 (30) 21 (38) 18 (31)
Race, n (%)
 White 57 (100) 53 (95) 57 (97)
 Hispanic 0 (0) 1 (2) 1 (2)
 Asian 0 (0) 2 (4) 1 (2)
Geographical region, n (%)
 Western Europea 21 (37) 22 (39) 17 (29)
 Eastern Europeb 26 (46) 20 (36) 29 (49)
 Canada and Australia 10 (18) 14 (25) 13 (22)
Median (range) age, yrs 59.0 (38–75) 63.0 (39–81) 62.0 (27–80)
Months since primary diagnosis, median (range) 1.1 (0.2–48.0) 1.1 (0.1–85.0) 1.1 (0.2–58.9)
Disease stage, n (%)
 Stage IIIB 4 (7) 6 (11) 6 (10) 
 Stage IV 53 (93) 50 (89) 53 (90)
ECOG performance status, n (%)
 0 15 (26) 18 (32) 18 (31)
 1 42 (74) 38 (68) 41 (69)
Smoking history, n (%)
 Current 22 (39) 10 (18) 27 (46)
 Former 28 (49) 35 (63) 30 (51)
 Never or occasional 7 (12) 11 (20) 2 (3)
Histology, n (%)
 Adenocarcinoma 29 (51) 26 (46) 33 (56)
 Squamous cell carcinoma 17 (30) 12 (21) 15 (25)
 Bronchoalveolar carcinoma 0 (0) 2 (4) 2 (3)
 Large-cell carcinoma 4 (7) 5 (9) 2 (3)
 Other 7 (12) 11 (20) 7 (12)
Prior surgery for NSCLC, n (%) 19 (33) 19 (34) 19 (32)
History of brain metastases, n (%) 12 (21) 17 (30) 15 (25)
a The Western Europe category comprises Belgium, France, and Spain.
b The Eastern Europe category comprises Czech Republic, Hungary, and Poland.
ECOG, Eastern Cooperative Oncology Group; PC, paclitaxel and carboplatin; NSCLC, non–small-cell lung cancer.
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Supplemental Digital Content 4, http://links.lww.com/JTO/
A372; Fig. 2C, D).
Overall, 167 of 172 patients (97%) had measurable disease 
at baseline. The ORR in arms 1, 2, and 3 was 15 of 55 (27%), 15 
of 56 (27%), and 14 of 56 (25%), respectively (Table 2). There 
was one complete response (arm 1). The median (95% CI) dura-
tion of response for arms 1, 2, and 3 was 4.2 (4.0–8.4) months, 
5.0 (4.1–7.1) months, and 4.6 (2.9–5.6) months, respectively; 
the median (range) time from randomization to response was 
1.4 (1.0–5.3) months, 2.8 (1.0–5.8) months, and 1.5 (1.2–4.1) 
months; and the disease control rate (ORR + stable disease) was 
42 of 55 (76%), 43 of 56 (77%), and 43 of 56 (77%).
Toxicity is summarized in Table 3. Patients receiving 
conatumumab had a higher incidence of grade 3 or more 
anemia (arm 1, 6 [11%]; arm 2, 5 [9%]) and thrombocytope-
nia (arm 1, 7 [12%]; arm 2, 4 [8%]) compared with placebo 
(1 [2%] each). Delays in, and reduced dosing of, conatu-
mumab occurred in 20 of 57 patients (35%) in arm 1 and 13 
of 53 patients (25%) in arm 2; Figure 1 summarizes discon-
tinuations. None of the 13 fatal treatment-emergent AEs were 
considered by the investigators to be related to conatumumab.
Anti-conatumumab binding antibodies were detected 
pretreatment in four patients (arm 1, n = 1; arm 2, n = 3) 
and transiently after treatment, in five patients (arm 1, n = 1; 
arm 2, n = 1; arm 3, n = 3). Neutralizing anti-conatumumab 
antibodies were detected in one patient in arm 3; however, 
because they were detected only once (study day 106), the 
result was likely a false positive.
Conatumumab exposure during the phase 1b and phase 
2 studies increased approximately dose proportionally after 
infusions of 3, 5, or 15 mg/kg conatumumab, plus PC. At the 
15-mg/kg dose, the mean serum maximum observed concen-
tration (C
max
) and area under the concentration versus time 
curve on day 1 of cycle 1 were 257 μg/mL and 44 h·mg/mL, 
respectively. Trough concentrations were 68 and 84 μg/mL in 
cycles 3 and 5, respectively. Small differences in paclitaxel and 
carboplatin plasma C
max
 were observed between the placebo 
and conatumumab arms, indicating little effect on paclitaxel 
and carboplatin exposures following conatumumab treat-
ment (Supplemental Table 4, Supplemental Digital Content 5, 
http://links.lww.com/JTO/A373).
Overall, 137 of 172 patients in the full analysis set were 
assessable for FCGR3A 158 polymorphisms. Among the 
V-allele carriers (V/V or F/V; n = 54) who received conatu-
mumab, there was a nonsignificant trend toward longer OS 
compared with placebo (HR [95% CI], 0.72 [0.43–1.23]); this 
effect was not observed among patients with two low-affinity 
binding alleles (F/F; HR [95% CI], 1.37 [0.66–2.86]; Fig. 4; 
Supplemental Table 5, Supplemental Digital Content 6, http://
links.lww.com/JTO/A374). Despite small sample numbers 
(n = 10), patients with two high-affinity binding alleles (V/V) 
who received conatumumab trended toward longer OS com-
pared with placebo (HR [95% CI], 0.49 [0.11–2.19]). The HR 
(95% CI) for OS for V-allele carriers versus the F/F geno-
type in the placebo arm was 1.28 (0.61–2.69), suggesting 
that patients with FCGR3A V carrier status did not perform 
TABLE 2.  Progression-Free Survival, Overall Survival, and Best Overall Tumor Response
Arm 1
PC + 3 mg/kg 
Conatumumab (n = 57)
Arm 2
PC + 15 mg/kg 
Conatumumab (n = 56)
Arm 3
PC + Placebo 
(n = 59)
Progression-free survival events, n (%) 51 (89) 55 (98) 57 (97)
Median (95% CI) progression-free survival time,a mo 5.4 (4.1–6.3) 4.8 (3.2–6.5) 5.5 (4.3–5.7)
 HR (95% CI)b 0.84 (0.57–1.24) 0.93 (0.64–1.35) —
 Log-rank test p value 0.405 0.573 —
 Tarone test p value 0.690
Deaths from any cause, n (%) 37 (65) 38 (68) 44 (75)
Median (95% CI) overall survival time,a mo 12.3 (8.4–14.8) 11.4 (8.0–14.1) 7.8 (7.0–11.5) 
 HR (95% CI)c 0.80 (0.52–1.24) 0.84 (0.54–1.30) —
 Log-rank test p value 0.283 0.509 —
 Tarone test p value 0.500
Patients with measurable disease at baseline, n 55 56 56
Best overall response assessment, n (%)
 Objective response 15 (27) 15 (27) 14 (25)
 Complete response 1 (2) 0 (0) 0 (0)
 Partial response 14 (25) 15 (27) 14 (25)
 Stable disease 27 (49) 28 (50) 29 (52)
 Progressive disease 7 (13) 7 (13) 9 (16)
 Unknownd 6 (11) 6 (11) 4 (7)
a Patients who had not progressed or had died at the last disease assessment were censored.
b HR for progression-free survival estimated using a stratified Cox proportional hazards model. An HR <1.0 indicates a lower average event rate and longer progression-free survival 
time for conatumumab relative to placebo.
c HR for overall survival estimated using an unstratified Cox proportional hazards model.
d Unknown indicates patients who had no postbaseline assessment or were unevaluable.
HR, hazard ratio; PC, paclitaxel and carboplatin; CI, confidence interval.
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FIGURE 2. A, Estimated progression-free survival per investigator assessment, (B), overall survival for PC plus conatumumab 
versus PC plus placebo, (C), estimated progression-free survival, and (D) overall survival for patients who received maintenance 
monotherapy. Patients who had not progressed or had died at their last assessment were censored. PC, paclitaxel and carboplatin.
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FIGURE 3. A, Forest plots for the hazard ratios (triangles) and 95% CIs (horizontal line) of potential covariates of disease 
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better when treated with PC alone. The interaction between 
FCGR3A 158 polymorphisms and conatumumab was not sig-
nificant (p = 0.326). No trends were observed for PFS or ORR 
(Supplemental Table 5, Supplemental Digital Content 6, http://
links.lww.com/JTO/A374; Supplemental Fig. 1, Supplemental 
Digital Content 7, http://links.lww.com/JTO/A375, which 
shows the estimated progression-free survival per investigator 
assessment for patients with at least 1 FCGR3A 158 polymor-
phism high-affinity (V/V or F/V) (A) or low-affinity (F/F) (B) 
binding allele. Patients who had not progressed or had died 
at their last disease assessment were censored. PC, paclitaxel 
and carboplatin.).
DISCUSSION
In this randomized phase 2 study, the addition of cona-
tumumab to PC did not improve outcomes in patients with 
previously untreated advanced NSCLC. Other randomized 
phase 2 studies have also demonstrated a lack of improved 
efficacy with the addition of DR4 or DR5 agonists to PC or 
PC plus bevacizumab in advanced NSCLC.13–15
Tumor histology is an important factor to consider when 
selecting targeted and cytotoxic therapies for patients with 
NSCLC because it can influence the treatment response.16 The 
results of this study suggest that conatumumab activity may 
have been confined to the patients with squamous histology. 
TABLE 3.  Incidence of Treatment-Emergent AEs
AEs, n (%)
Arm 1 
PC + 3 mg/kg 
Conatumumab (n = 57)
Arm 2
PC + 15 mg/kg 
Conatumumab (n = 53)
Arm 3
PC + Placebo 
(n = 57)a
Patients with ≥1 AE 51 (89) 51 (96) 54 (95)
Patients with ≥1 grade ≥3 AE 34 (60) 33 (62) 37 (65)
Patients with ≥1 serious AE 21 (37) 18 (34) 22 (39)
Fatal AEsb 4 (7) 4 (8) 5 (9)
AEs occurring in ≥10% of all patients
 Alopecia 26 (46) 26 (49) 24 (42)
 Fatigue 17 (30) 18 (34) 20 (35)
 Dyspnea 16 (28) 14 (26) 10 (18)
 Anemia 15 (26) 12 (23) 10 (18)
 Decreased appetite 15 (26) 9 (17) 15 (26)
 Nausea 15 (26) 14 (26) 20 (35)
 Asthenia 12 (21) 12 (23) 11 (19)
 Cough 12 (21) 11 (21) 8 (14)
 Paraesthesia 12 (21) 3 (6) 9 (16)
 Thrombocytopenia 11 (19) 12 (23) 3 (5)
 Vomiting 11 (19) 13 (25) 10 (18)
 Diarrhea 10 (18) 16 (30) 9 (16)
 Chest pain 9 (16) 5 (9) 5 (9)
 Insomnia 9 (16) 8 (15) 3 (5)
 Constipation 8 (14) 8 (15) 14 (25)
 Myalgia 8 (14) 8 (15) 8 (14)
 Pyrexia 8 (14) 8 (15) 7 (12)
 Peripheral neuropathy 7 (12) 11 (21) 8 (14)
 Arthralgia 6 (11) 7 (13) 12 (21)
 Peripheral sensory neuropathy 5 (9) 7 (13) 9 (16)
 Headache 3 (5) 9 (17) 5 (9)
Grade ≥3 AEs occurring in ≥3% of all patients
 Neutropenia 8 (14) 5 (9) 9 (16)
 Thrombocytopenia 7 (12) 4 (8) 1 (2)
 Anemia 6 (11) 5 (9) 1 (2)
 Dyspnea 4 (7) 3 (6) 3 (5)
 Chest pain 2 (4) 2 (4) 3 (5)
 Pulmonary embolism 2 (4) 2 (4) 2 (4)
 Asthenia 1 (2) 1 (2) 3 (5)
 Fatigue 1 (2) 2 (4) 3 (5)
a One patient randomized to the placebo arm received 3 mg/kg conatumumab and is included in the safety analysis set of that arm.
b None of the fatal AEs was considered by investigators to be related to treatment with conatumumab.
AE, adverse event; PC, paclitaxel and carboplatin.
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However, the mechanisms underlying such a potential difference 
in activity between patients with squamous and nonsquamous 
histology are unclear. Although DR4 and DR5 are expressed by 
both squamous and nonsquamous tumors,17 the expression of 
DR5 may be heterogeneous across NSCLC histologies.15 Thus, 
assessing the expression of DR4 or DR5 and other markers 
(e.g., caspase 8 and cellular FLICE inhibitory protein)18 within 
histologic subtypes could be useful for generating hypotheses 
related to patient selection in future trials.
The longer PFS and OS times observed with mainte-
nance conatumumab monotherapy are interesting and suggest 
that continuation monotherapy with DR4 or DR5 agonists may 
be important for maximizing benefit, as with other treatments 
in this setting (e.g., pemetrexed and cetuximab).1 However, 
consistent with the initial evidence of antitumor activity in the 
phase 1 first-in-human monotherapy study,8 it is also possible 
that conatumumab may have greater activity as a single agent 
than in combination with chemotherapy.
Consistent with the phase 1b study,9,10 conatumumab 
plus PC was generally well tolerated. No dose-related trends 
in the incidence of AEs were observed. The incidence of grade 
3 or higher anemia and thrombocytopenia was greater in the 
conatumumab arms compared with placebo. Several of the 
most frequently reported AEs (fatigue, dyspnea, anemia, and 
thrombocytopenia) were reported in the conatumumab first-
in-human study8 and in studies of DR4 or DR5 agonists in 
NSCLC15,19 or solid tumors.19–23 Because the detected anti-
conatumumab antibodies were not neutralizing, they likely 
did not affect the clinical activity of conatumumab.
Serum conatumumab concentrations were consistent 
with those reported in the first-in-human monotherapy study.8 
Trough concentrations at the 15-mg/kg dose (68 and 84 μg/mL 
in cycles 3 and 5, respectively) exceeded the concentrations 
required to achieve 90% maximal tumor growth inhibition in 
a preclinical xenograft model,7 suggesting that conatumumab 
administration once every 3 weeks provided adequate exposure.
Preclinical studies have indicated that apoptosis induc-
tion by agonistic DR5 antibodies requires FcγR crosslink-
ing.24,25 We examined whether FCGR3A 158 polymorphisms, 
which result in high- and low-affinity forms of FcγRIIIa,26 
predicted outcome in patients who received conatumumab. 
The trend toward OS benefit among V-allele carriers in the 
conatumumab arms was the most robust in patients with two 
high-affinity binding alleles (V/V). Although these data are 
limited by the small sample size and low frequency of the 
high-affinity binding allele, to our knowledge, this is the first 
reported potential association between outcome and FCGR3A 
F158V genotype in NSCLC patients treated with an agonistic 
DR5 monoclonal antibody. It is plausible that patients with the 
high-affinity allele, and consequently the high-affinity form of 
FcγRIIIa, may have experienced additional benefit from cona-
tumumab treatment, as a result of enhanced binding of the 
conatumumab Fc domain, DR5 crosslinking, and induction of 
tumor cell death; however, this has not been verified. Greater 
clinical benefit from the immunoglobulin G1 monoclonal 
antibodies rituximab, cetuximab, and trastuzumab, which 
may function through antibody-dependent, cell-mediated 
cytotoxicity, has been observed in patients with two high-
affinity binding alleles.27–29 In this study, it is unknown 
whether conatumumab or antibody-dependent cell-mediated 
cytotoxicity induced apoptosis. Potential circulating biomark-
ers of apoptosis, such as caspase-cleaved cytokeratin-18,24,30 
were not assessed because of the small sample size.
The strengths of this study were its randomized, 
 double-blind design, placebo-control arm, and assessment 
of two conatumumab doses. However, it should be noted that 
the study was not designed to allow statistical inference but, 
rather, was designed to estimate the treatment effect (assessed 
by PFS) of adding conatumumab to PC. Although this study 
provided reasonable precision for the estimates of efficacy and 
safety, the results do not support a larger study. There are no 
plans for further evaluation of conatumumab in lung cancer.
In conclusion, although well tolerated, the addition of 
conatumumab to PC did not improve efficacy in unselected 
patients with previously untreated advanced NSCLC. 
However, investigation of the role of tumor histology and FcR 
cross-linking in the efficacy of DR agonists may be warranted.
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APPENDIX
FCGR3A Allelic Discrimination Assay Methods
The forward primer (TTCCAAAAGCCACACTCAA 
ACAC) hybridizes to a region with a single-nucleotide dif-
ference between FCGR3A and FCGR3B. A mismatch was 
incorporated three nucleotides from the 3′ end to maxi-
mize discriminatory power. The reverse primer sequence 
was TGGTGATGTTCACAGTCTCTGAAGA. One probe 
was specific for each of two single-nucleotide polymor-
phism alleles (FAM-TTACTCCCAAAAAGCCCCCTGCA-
BHQ; YAK-TACTCCCAACAAGCCCCCTGCA-BHQ; 
FAM=carboxyfluorescein and YAK=Yakima yellow). Standard 
allelic discrimination assay conditions were used with 2X 
TaqMan Universal PCR Master Mix (Applied Biosystems, 
Foster City, CA) and a 7900HT Sequence Detection System 
(Applied Biosystems).
Biomarker Statistical Analyses
The effect of FCGR3A F158V polymorphisms on the 
treatment effect of conatumumab on both progression-free 
survival and overall survival was explored using Kaplan-Meier 
estimates by FCGR3A genotype and treatment. Hazard ratios 
for conatumumab versus placebo in each genotype were 
obtained using Cox proportional hazard models. The objective 
response rate was summarized using descriptive statistics by 
genotype and treatment. To evaluate the prognostic effect 
of FCGR3A F158V polymorphisms in patients treated with 
placebo, HRs between specific FCGR3A genotypes within the 
placebo group were calculated.
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